The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit
- PMID: 40037587
- PMCID: PMC12048059
- DOI: 10.1093/rheumatology/keaf037
The use of combination advanced therapies in psoriatic arthritis: results from a UK multi-centre audit
References
-
- Najm A, Goodyear CS, McInnes IB, Siebert S. Phenotypic heterogeneity in psoriatic arthritis: towards tissue pathology-based therapy. Nat Rev Rheumatol 2023;19:153–65. - PubMed
-
- Mease PJ, Genovese MC, Weinblatt ME et al. Phase II study of ABT-122, a tumor necrosis factor- and interleukin-17A-targeted dual variable domain immunoglobulin, in patients with psoriatic arthritis with an inadequate response to methotrexate. Arthritis Rheumatol (Hoboken, NJ) 2018;70:1778–89. - PMC - PubMed
-
- Abignano G, Fadl N, Merashli M et al. A comparison of apremilast monotherapy and combination therapy for psoriatic arthritis in a real-life setting: data from the Leeds Combined Psoriatic Service. J Ame Acad Dermatol 2019;80:1796–8. - PubMed
-
- Shurey M, Yip A, Ziouzina O, Chan J, Dutz JP. Combination therapy with tofacitinib and IL-12/23, IL-23, or IL-17A inhibition for the treatment of refractory psoriatic arthritis: a case series. JCR J Clin Rheumatol 2022;28:e626–e8. - PubMed
LinkOut - more resources
Full Text Sources